Series B Growth Arintra has recently closed a $25M Series B round raising total funding to $51M, signaling strong investor confidence and rapid scaling potential. This suggests a favorable window for enterprise sales conversations with larger health systems seeking AI-driven revenue assurance solutions to complement their growth.

Revenue Uplift Promise The platform claims 5%+ revenue uplift, 12%+ reduction in accounts receivable days, and 43%+ fewer denials. These quantified outcomes provide solid value storytelling for ROI-driven buying committees and negotiation leverage when targeting hospitals and health systems.

Enterprise Momentum Recent partnerships and expansion activity include Mercyhealth and multiple enterprise deals by end of 2025, indicating a scalable deployment model within multi-site health systems. Target similar regional and multi-facility networks to maximize implementation impact.

EHR Native Advantage Arintra operates directly within the EHR with autonomous AI coding and zero workflow changes, reducing data integrity risk. This compelling differentiator can be emphasized to IT and CMIO stakeholders to ease procurement barriers and speed buy-in.

Funding-backed credibility Backed by reputed investors such as Define Ventures, Peak XV Partners, Endeavor Health Ventures, and Y Combinator connections, Arintra’s financial backing and pedigree can be leveraged to build trust with procurement and risk-averse health systems pursuing innovative vendors.